Company news
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) news
Every Fulcrum Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
March 5, 2024
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
February 27, 2024
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
February 20, 2024
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 6, 2024
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
November 9, 2023
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
November 7, 2023
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
October 31, 2023
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
September 22, 2023
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
September 7, 2023
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
August 22, 2023
Fulcrum Therapeutics Appoints Chief Financial Officer
August 3, 2023
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
August 3, 2023
Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET
July 27, 2023
Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
July 10, 2023
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
May 15, 2023
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023
May 15, 2023
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET
May 8, 2023
Fulcrum Therapeutics Announces CFO Resignation
April 5, 2023
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
March 9, 2023
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
March 6, 2023
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
February 24, 2023
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
February 8, 2023
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
January 17, 2023
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
January 17, 2023
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
January 4, 2023
Fulcrum Therapeutics Announces CEO Transition
January 4, 2023
Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference
December 1, 2022
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 11, 2022
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results
November 8, 2022
Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer
November 7, 2022
Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET
November 2, 2022
Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences
November 1, 2022
Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada
October 12, 2022
Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences
September 6, 2022
Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit
August 16, 2022
Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock
August 15, 2022
Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
August 11, 2022
Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET
August 4, 2022
Fulcrum Therapeutics Announces Departure of Chief Medical Officer
July 11, 2022
Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
July 5, 2022
Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial
June 10, 2022
Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria
May 12, 2022
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 9, 2022
Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference
May 5, 2022
Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET
May 2, 2022
Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology’s Annual Meeting
April 1, 2022
Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
March 17, 2022
Fulcrum Therapeutics® Presents Data Highlighting Reachable Workspace (RWS) as Relevant Functional Endpoint in Facioscapulohumeral Muscular Dystrophy (FSHD) at MDA Clinical and Scientific Conference
March 14, 2022
Fulcrum Therapeutics® Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results
March 3, 2022
Fulcrum Therapeutics® Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
March 3, 2022